Department of Psychiatry, University of California San Diego, 9500 Gilman Drive MC 0804, La Jolla, CA 92093-0804, USA.
Neuropharmacology. 2012 Mar;62(3):1381-90. doi: 10.1016/j.neuropharm.2011.06.013. Epub 2011 Jun 29.
Schizophrenia is a debilitating cognitive disorder. The link between cognitive debilitation and functional outcome in patients with schizophrenia has prompted research to develop procognitive therapies. It is hoped that by improving cognition in these patients, their functional outcome will also improve. Although no established treatments exist as yet, progress has been made toward understanding how to evaluate putative compounds in the clinic. Genetic mouse models and pharmacological rat models of cognitive disruption are being developed that may help to evaluate these putative compounds preclinically. Considering the increased number of genetic mouse models relevant to schizophrenia, there is a need to evaluate pharmacological manipulations on cognition in mice. Here we review the current literature on mouse pharmacological models relevant to schizophrenia. In this review, we discuss where different pharmacological effects between rats and mice on cognitive tasks are observed and assess the validity offered by these models. We conclude that the predictive validity of these models is currently difficult to assess and that much more needs to be done to develop useful mouse pharmacological models of cognitive disruption in schizophrenia.
精神分裂症是一种使人虚弱的认知障碍。精神分裂症患者认知能力下降与功能结果之间的联系促使人们开展了认知增强治疗的研究。人们希望通过改善这些患者的认知能力，也能改善他们的功能结果。尽管目前还没有确立的治疗方法，但在理解如何在临床上评估潜在化合物方面已经取得了进展。正在开发用于认知障碍的遗传小鼠模型和药理学大鼠模型，这可能有助于在临床前评估这些潜在化合物。鉴于与精神分裂症相关的遗传小鼠模型数量不断增加，有必要评估对认知的药理学干预在小鼠身上的效果。在这里，我们回顾了与精神分裂症相关的小鼠药理学模型的现有文献。在这篇综述中，我们讨论了在认知任务中观察到大鼠和小鼠之间不同的药理学作用的地方，并评估了这些模型提供的有效性。我们得出的结论是，这些模型的预测有效性目前难以评估，还需要做更多的工作来开发用于精神分裂症认知障碍的有用的小鼠药理学模型。
